Astellas Pharma Inc. (ALPMY)
OTCMKTS · Delayed Price · Currency is USD
15.74
+0.24 (1.55%)
At close: Feb 6, 2026
Astellas Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 2,060,614 | 1,912,323 | 1,603,672 | 1,518,619 | 1,296,163 | 1,249,528 | |
Revenue Growth (YoY) | 10.33% | 19.25% | 5.60% | 17.16% | 3.73% | -3.94% |
Cost of Revenue | 391,617 | 349,206 | 292,485 | 288,353 | 253,009 | 246,063 |
Gross Profit | 1,668,997 | 1,563,117 | 1,311,187 | 1,230,266 | 1,043,154 | 1,003,465 |
Selling, General & Admin | 836,929 | 843,032 | 740,110 | 630,272 | 548,840 | 504,316 |
Research & Development | 295,113 | 327,651 | 294,187 | 276,128 | 246,010 | 224,489 |
Other Operating Expenses | -12,411 | -7,868 | 53,464 | 53,778 | 1,876 | -35 |
Operating Expenses | 1,252,410 | 1,299,577 | 1,186,581 | 998,614 | 825,009 | 752,533 |
Operating Income | 416,587 | 263,540 | 124,606 | 231,652 | 218,145 | 250,932 |
Interest Expense | -11,219 | -13,952 | -7,423 | -3,217 | -2,315 | -2,118 |
Interest & Investment Income | 5,671 | 6,885 | 8,851 | 5,253 | 862 | 760 |
Earnings From Equity Investments | -1,265 | -259 | -3,165 | 1,260 | 489 | 478 |
Currency Exchange Gain (Loss) | -2,478 | -18,578 | -807 | -10,124 | 8,172 | -2,332 |
Other Non Operating Income (Expenses) | -220 | -218 | -1,723 | 2,303 | -2,431 | 72 |
EBT Excluding Unusual Items | 407,076 | 237,418 | 120,339 | 227,127 | 222,922 | 247,792 |
Merger & Restructuring Charges | -5,223 | -15,523 | -25,407 | -4,510 | -19,556 | -9,293 |
Gain (Loss) on Sale of Investments | -2,516 | -2,516 | -253 | -5,007 | 5,084 | 10,558 |
Gain (Loss) on Sale of Assets | 4,072 | 1,049 | 9,735 | 212 | 24,234 | 24 |
Asset Writedown | -12,718 | -187,618 | -78,931 | -83,964 | -74,850 | -101,746 |
Legal Settlements | -1,573 | -1,573 | -514 | -1,497 | -948 | -2,012 |
Pretax Income | 389,118 | 31,237 | 24,969 | 132,361 | 156,886 | 145,323 |
Income Tax Expense | 66,263 | -19,510 | 7,924 | 33,647 | 32,800 | 24,734 |
Net Income | 322,910 | 50,747 | 17,045 | 98,714 | 124,086 | 120,589 |
Net Income to Common | 322,910 | 50,747 | 17,045 | 98,714 | 124,086 | 120,589 |
Net Income Growth | - | 197.72% | -82.73% | -20.45% | 2.90% | -38.29% |
Shares Outstanding (Basic) | 1,791 | 1,790 | 1,793 | 1,820 | 1,850 | 1,857 |
Shares Outstanding (Diluted) | 1,802 | 1,797 | 1,800 | 1,825 | 1,851 | 1,858 |
Shares Change (YoY) | 0.64% | -0.14% | -1.39% | -1.38% | -0.41% | -1.03% |
EPS (Basic) | 180.31 | 28.35 | 9.50 | 54.24 | 67.08 | 64.93 |
EPS (Diluted) | 179.17 | 28.24 | 9.47 | 54.09 | 67.05 | 64.90 |
EPS Growth | - | 198.21% | -82.49% | -19.33% | 3.31% | -37.64% |
Free Cash Flow | 407,026 | 157,509 | 134,419 | 291,326 | 226,705 | 275,459 |
Free Cash Flow Per Share | 225.84 | 87.64 | 74.69 | 159.63 | 122.50 | 148.24 |
Dividend Per Share | 37.000 | 74.000 | 70.000 | 60.000 | 50.000 | 42.000 |
Dividend Growth | -48.61% | 5.71% | 16.67% | 20.00% | 19.05% | 5.00% |
Gross Margin | 80.99% | 81.74% | 81.76% | 81.01% | 80.48% | 80.31% |
Operating Margin | 20.22% | 13.78% | 7.77% | 15.25% | 16.83% | 20.08% |
Profit Margin | 15.67% | 2.65% | 1.06% | 6.50% | 9.57% | 9.65% |
Free Cash Flow Margin | 19.75% | 8.24% | 8.38% | 19.18% | 17.49% | 22.05% |
EBITDA | 608,504 | 462,672 | 282,446 | 337,390 | 297,829 | 323,584 |
EBITDA Margin | 29.53% | 24.19% | 17.61% | 22.22% | 22.98% | 25.90% |
D&A For EBITDA | 191,917 | 199,132 | 157,840 | 105,738 | 79,684 | 72,652 |
EBIT | 416,587 | 263,540 | 124,606 | 231,652 | 218,145 | 250,932 |
EBIT Margin | 20.22% | 13.78% | 7.77% | 15.25% | 16.83% | 20.08% |
Effective Tax Rate | 17.03% | - | 31.74% | 25.42% | 20.91% | 17.02% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.